Kronos Bio (KRON)
(Delayed Data from NSDQ)
$0.77 USD
-0.20 (-20.61%)
Updated May 24, 2024 03:59 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
Kronos Bio, Inc. [KRON]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Lanra Discontinued Based on Initial Data; Lowering PT to $2.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Corporate Restructuring Announced; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Interim Clinical Data for KB-0742 Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
KB-0742 Data at Upcoming Triple Meeting; 2Q23 Financials; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
KB-0742 Clinical Data Approaching; 2022 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Ento Trial Culled; CDK9 Data Imminent; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Upcoming Catalysts; 1Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Kronos Expands Tempus Collaboration; 3Q21 Financials; Modulating PT to $36
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
KB-0742 Shows Encouraging Preclinical Anti-Tumor Activity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Lanraplenib Cleared to Enter Clinical Assessment by FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Kronos Bio, Inc.
Industry: Medical - Biomedical and Genetics
Destroying Dysregulated Transcription in Cancer; Initiate at Buy and $35 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
|